ClinicalTrials.gg
RecruitingNCT07797855Updated Sep 30, 2026

A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People

A Phase 1 interventional study of NNC0705-0002 and Placebo in Healthy Volunteers and Cardiometabolic Diseases, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 30, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is testing NNC0705-0002, a new medicine that is being developed for conditions where inflammation may contribute to heart and metabolic health problems. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, target engagement, and metabolism of NNC0705-0002 after single and multiple doses in healthy adults. NNC0705-0002 or a placebo (a substance that looks like the study medicine but contains no active medicine), and the treatment they receive may be chosen by chance. NNC0705-0002 is a new medicine that is not yet approved for doctors to prescribe. Depending on the part of the study, participation may last for up to about 7 weeks, including screening, treatment, and follow-up visits.

02

Conditions studied

  • Healthy Volunteers
  • Cardiometabolic Diseases
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women of non-.
  • Age 18-55 years (both inclusive) at the time of signing the .
  • (BMI) between 18.5 to 29.9 kilogram per square metre (kg/m\^2) (both inclusive) at screening.
  • Body weight: greater than or equal to (≥) 50.0 kg at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Any of the below laboratory safety parameters at screening outside normal range, see designated reference range documents for specific values.

    • (ALT) greater than (>) (ULN)
    • Aspartate aminotransferase (AST) >ULN
    • Total (TBL) >ULN
    • Creatinine >ULN
    • (INR) >ULN
    • High-sensitivity C-reactive protein (hsCRP) greater than (>)5 milligram per liter (mg/L) (males) and >8 mg/L (females)
  • Use of prescription medicinal products or vaccines within 14 days before dosing and/or non-prescription medicinal products within 7 days before dosing. Exceptions are: Topical medications not reaching systemic circulation; less than once per week of over-the-counter acetaminophen/paracetamol and/or nonsteroidal anti-inflammatory drugs at their labelled doses for mild pain; vitamins at their labelled doses.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    NNC0705-0002

    Participants will receive NNC0705-0002 administered orally as a single ascending dose (SAD), multiple ascending dose (MAD), or under fed/fasted conditions.

    Drug: NNC0705-0002

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC0705-0002 administered orally as a SAD, MAD, or under fed/fasted conditions.

    Drug: Placebo

Interventions

  • DrugNNC0705-0002

    Participants will receive oral capsule of NNC0705-0002.

  • DrugPlacebo

    Participants will receive oral capsule of placebo matched to NNC0705-0002.

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAEs)

    Measured as number of events.

    Time frame: From time of dosing (day 1) to day 7

  2. Number of TEAEs

    Measured as number of events.

    Time frame: From time of dosing (day 1) to day 13

  3. AUC0-t, SD; the area under the NNC0705- 0002 plasma concentration-time curve from time 0 to last measurable plasma concentration after a single dose

    Measured as hour micromolar (h\*μM).

    Time frame: From pre-dose (day 1 or day 10) to day 6 or day 15

  4. Total recovery of administered radiolabelled NNC0705- 0002-related material (sum urine and faeces)

    Measured as percentage (%) of dose.

    Time frame: From time of dosing (day 1) to no later than day 21

Secondary outcomes

  1. AUC0-∞, SD; the area under the NNC0705- 0002 plasma concentration-time curve from time 0 to infinity after a single dose

    Measured as h\*μM.

    Time frame: From pre-dose (day 1) to day 7

  2. Cmax, SD; the maximum observed plasma concentration of NNC0705-0002 after a single dose

    Measured as micromolar (μM).

    Time frame: From pre-dose (day 1) to day 7

  3. AUCtau, MD; the area under the NNC0705- 0002 plasma concentration-time curve from time 0 to tau after the last dose

    Measured as h\*μM.

    Time frame: From pre-dose (day 7) to tau after last dose (day 8)

  4. Cmax, MD; the maximum observed plasma concentration of NNC0705-0002 after last dose

    Measured as μM.

    Time frame: From pre-dose (day 7) to day 13

  5. AUC0-∞, SD; the area under the NNC0705- 0002 plasma concentration-time curve from time 0 to infinity after a single dose

    Measured as h\*μM.

    Time frame: From pre-dose (day 1 or day 10) to day 6 or day 15

  6. Cmax, SD; the maximum observed plasma concentration of NNC0705-0002 after a single dose

    Measured as μM.

    Time frame: From pre-dose (day 1 or day 10) to day 6 or day 15

  7. Dose-normalised AUC0-∞, SD; the area under the NNC0705-0002 or radiolabelled NNC0705-0002-related material total radioactivity (TRA) plasma concentration-time curve from time 0 to infinity after a single dose divided by dose

    Measured as hour micromolar per milligram (h\*μM/mg).

    Time frame: From pre-dose (day 1) to day 17

  8. Total amount of radiolabelled NNC0705-0002- related material excreted in urine

    Measured as % of dose.

    Time frame: From pre-dose (day 1) to day 6

  9. Total amount of radiolabelled NNC0705-0002- related material excreted in faeces

    Measured as % of dose.

    Time frame: From pre-dose (day 1) to day 6

  10. AUC0-∞,14C,SD; area under the plasma concentration-time curve of radiolabelled NNC0705-0002-related material (TRA) from time 0 to infinity after a single dose

    Measured as hundreds of nanomoles per litre (h\*nmol/L).

    Time frame: From pre-dose (day 1) to day 9

  11. Number of TEAEs

    Measured as number of events.

    Time frame: From time of dosing (day 1) to day 17

  12. AUC0-∞,14C,SD; area under the plasma concentration-time curve of radiolabelled NNC0705-0002-related material (TRA) from time 0 to infinity after a single dose

    Measured as h\*nmol/L.

    Time frame: From pre-dose (day 1) to no later than day 21

  13. Cmax,14C,SD: maximum observed plasma concentration of radiolabelled NNC0705-0002- related material (TRA) after a single dose

    Measured as nanomole per litre (nmol/L).

    Time frame: From pre-dose (day 1) to no later than day 21

  14. AUC0-∞,SD; area under the plasma concentration-time curve of NNC0705- 0002 from time 0 to infinity after a single dose

    Measured as h\*nmol/L.

    Time frame: From pre-dose (day 1) to day 5

  15. Cmax,SD: maximum observed plasma concentration of NNC0705-0002 after a single dose

    Measured as nmol/L.

    Time frame: From pre-dose (day 1) to day 5

  16. Number of TEAEs

    Measured as number of events.

    Time frame: From time of dosing (day 1) to day 23

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Sep 1, 2026
StartActual
Sep 2, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
ICON - location Groningen is now Recruiting
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    ICON - location Groningen is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07797855
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Sep 2, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion